Rheumatoid Arthritis News

 
 
  • TNFi Unlikely to Raise Cancer Recurrence Risk in RA Patients with rheumatoid arthritis who have had cancer can, in general, be treated with tumor necrosis factor inhibitors without increasing cancer recurrence risk, new data showed.
  • Adalimumab Appears Safe for Treating Pediatric Patients With Autoimmune Disease Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn's disease (CD), according to data from company-sponsored clinical trials.
  • Alert European Union Clears Tofacitinib for Ulcerative Colitis The JAK inhibitor is indicated for adults with moderately to severely active ulcerative colitis who have failed to respond adequately to or are intolerant of other therapies.
  • Resistance to Biologics in RA Underestimated At least 6% of patients with RA were refractory to biologic DMARDs, a study found; however, another expert says the incidence may be much higher.
  • Updated Exercise Guidelines for Adults With Arthritis New recommendations from EULAR on physical activity for patients with inflammatory or osteoarthritis mirror those for the general population.
  • Rheumatologists Cautioned to Avoid Overtreatment Six common approaches to treating inflammatory rheumatic diseases might lead to overdiagnosis and overtreatment, an expert warns. Another expert says overdiagnosis is less common, however.
  • Drug Combination Boosts Older Adults' Immunity in Early Trial A phase 2a randomized, placebo-controlled clinical trial showed that a combination of drugs decreases the incidence of infections, including influenza and pneumonia, in older adults.
  • EULAR 2018Obesity in Women and Smoking in Men Strongly Predict Lack of Remission in Early RA Obesity in women and current smoking in men appear to be the strongest predictors of lack of remission in early rheumatoid arthritis (RA) within one year, according to new research presented June 13 at EULAR 2018, the annual meeting of the European League Against Rheumatism, in Amsterdam.
  • DMARDs Ineffective Against Osteoarthritis, Study Finds Neither conventional DMARDs nor biologics are effective treatments for osteoarthritis, a meta-analysis of randomized controlled trials has found.
  • Disease-Modifying Antirheumatic Drugs Cut RA Risk Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report.
  • Novartis Touts Effectiveness, Safety of Autoimmune Drug Copies Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade (infliximab) and Amgen Inc's Enbrel (etanercept), citing studies it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.
  • EULAR 2018Blood Test Predicts Onset of Rheumatoid Arthritis A biomarker can identify risk for rheumatoid arthritis disease development, which could lead to early intervention, new research shows.
  • Lilly's Lupus Treatment Succeeds in Mid-Stage Trial Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.
  • Safe Stopping of Tocilizumab in RA: MTX Helps Patients with rheumatoid arthritis who achieve 6 months of remission or low disease activity by taking methotrexate plus tocilizumab can usually stop tocilizumab; restarting is effective if flares occur.
  • AbbVie's Rheumatoid Arthritis Drug Succeeds in Late-stage Study Abbvie Inc said on Tuesday its experimental drug met the main goal of halting progression of moderate-to-severe rheumatoid arthritis in a late-stage trial.
  • EULAR 2018New Osteoarthritis Treatments Garnering Attention at EULAR Interest in osteoarthritis is growing as new treatment options emerge, and insights will be discussed at the upcoming European League Against Rheumatism Congress (EULAR).
  • Alert FDA Approves Baricitinib for Rheumatoid Arthritis The FDA has approved baricitinib 2-mg tablets for the treatment of moderately to severely active rheumatoid arthritis in adults, but declined to approve the 4-mg tablets.
  • In Louisiana Jail, Deaths Mount as Mental Health Pleas Unheeded The East Baton Rouge Parish Prison, a squat brick building with low-slung ceilings and walls sometimes smeared with feces, is the face of a paradigm shift: penitentiaries as mental health care providers. Across the United States thousands of jails are sheltering a wave of inmates accused of crimes and serving time while suffering from illnesses ranging from depression to schizophrenia.
  • Gap in Regulating Biotech Drug Copies Prompts WHO to Step in Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.
  • Prenatal TNF Inhibitor Exposure Not Linked to Serious Infections Children of women with rheumatoid arthritis (RA) who are exposed to tumor necrosis factor-alpha inhibitors (TNFis) in the womb are not at markedly increased risk of serious infections, new findings suggest.
оксандролон для женщин

http://pharmacy24.com.ua

http://pillsbank.net